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Abstract Endometrial cancer belongs to the commonest ma-
lignancy in females after breast cancer, malignant neoplasm of
female genitals in Europe and North America but there is still
not significant improvement as far as the curability of this
neoplasm is concerned, especially its advanced forms. That is
why there is need to define new factors that could be not only
diagnostic but also predictve factors. In present study we
analyzed the mRNA PTEN expression by quantitative real-
time polymerase chain reaction (Q-PCR) in 123 women of
endometrial carcinoma and 14 women of control group.
Moreover we assessed oestrogen (ER) and progesterone re-
ceptors (PgR) in all cases. We defined the correlation between
expression of PTEN gene and receptors and between PTEN
expression and maturity grade of cancer. Neoplasm advance-
ment grade G1was diagnosed in 82.11% of patients (n =101),
G2 in 9.76 % of patients (n =12) and G3 in 8.13 % of patients
(n =10). Presence of ER and PgR and decreased expression of
PTEN gene was found in majority of patients with endome-
trial cancer (79.12 % and 59.34 % respectively) and the most
numerous group was with weak expression of ER and strong
expression of PgR. There was no statistically significant dif-
ference in gene expression depending on receptors expression
nor maturity grade of cancer (p >0.05). Evaluation of expres-
sion ofPTEN genemay turn out to be a very useful tool aimed
at qualifying patients for different therapies of endometrial
cancer and at searching of new diagnostic and therapeutic
methods of this cancer independently on its receptor status
nor maturity grade of cancer.
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Introduction
Endometrial cancer (EC) is the most frequent, after breast
cancer, malignant neoplasm of female genitals in Europe and
North America and the fourth among all malignant neoplasms
in women, after breast cancer, lung cancer and large intestine
cancer [1–3]. EC cancerogenesis is not fully recognized pro-
cess regarding many risk factors. Prognostic factors common-
ly used to identification of endometrial cancer present an
incomplete picture of the tumour biology of endometrial
cancer [4]. Therefore, investigation of other prognostic factors
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is of special clinical relevance, particularly in view of the
unexpectedly progressive course of the disease and frequent
relapses in some cases. PTEN is the most frequently mutated
gene identified yet in endometrial cancers [5, 6].
PTEN (Phosphatase and Tensin Homologue) is a supressor
gene located in chromosome 10q23. It codes lipid and protein
phosphatase (PTEN) and contributes to the control of the
proliferation, differentiation and apoptosis process [7]. The
PTEN tumor suppressor gene regulates the oncogenic phos-
phatidylinositol 3-kinase (PI3K ) signaling pathway that is
involved in carcinogenesis. Downstream of those two path-
ways is AKT, a serine-threonine kinase that is regulated by
PI3K and influences apoptosis and cell proliferation [7].
Alterations in the PTEN-PI3K-AKT pathways have been re-
ported for hormone-related tumors among women, including
breast, ovarian [8, 9] and endometrial [5, 6] cancers. Until now
it has been found that PTEN mutations are the most frequent
genetic changes in endometrial cancer of type I and occur in
25–83 % of tumours, including tumours with microsatellite
instability [10]. PTEN inactivation was described most fre-
quently in early stages of endometrial cancer whilst in other
types of neoplasms it occurs in their more advanced stages and
is connected with cancer cells metastases [11]. Due to this fact,
PTEN may be a good endometrial cancer marker, already in
the early stage of its development [12, 13].
PTEN expression correlates negatively with neoplasm ad-
vancement grade. PTEN mutations, occurring in an early
development stage of the tumour, result in lack of cell differ-
entiation, which might be connected with a more aggressive
neoplasm type [14, 15].
In light of substantial evidence that the progression of en-
dometrial cancer can be associated with PTEN , it seems reason
able to check a possible correlation between the expression of
this gene and clinical status of endometrial cancer patients.
Material and Methods
Patients
Endometrium was obtained from 137 women who underwent
hysterectomy with adnexectomy in the Gynaecological and
Obstetric Clinical Hospital of the University of Medical Sci-
ences in Poznan between 2004 and 2006. Tumour tissues were
obtained from women with endometrial adenocarcinoma.
Clinical data for the patients and histological data were regis-
tered. There were 123 women and their mean age was 60,6±
10.0 years (range: 34–85 years). Endometrium from age-
matched, cancer-free women (n =14) served as control (the
mean age 60,1±7.6). Endometrial carcinomas were classified
according to the criteria of the International Federation of
Gynecology and Obstetrics (FIGO). Histological typing and
grading were done according to the WHO classification.
Before the surgery each patient underwent a subject exam-
ination, a gynaecological examination, an ultrasonographic
examination by means of an intravaginal probe and preoper-
ative laboratory tests. Moreover, a conscious written consent
to operation and uptake of segments of the endometrium for
the sake of scientific research was signed by every patient.
Tissue material obtained after the operation from each
patient was divided into two parts. From one part wax blocks
were created, and after that specimens for histopathological
assessment dyed with hematoxilin and eosin (H + E). The
other part of the material was frozen in −80 °C. The proce-
dures, used in the study, were approved by the Ethical Com-
mittee of the Medical University of Poznań (Poland).
Evaluation of ER and PR
ER and PR status was determined by immunohistochemical
method as part of the routine clinical practice. In this method
ready antibodies Monoclonal Mouse Anti-Human Progester-
one Receptor Clone PgR 636 and Monoclonal Mouse Anti-
Human Oestrogen Receptor α Clone ER 1D5 were used.
Using the immunohistochemical assay, tumors were classified
as positive if more than 10 % of the cells showed nuclear
staining for the receptor. This information was received to-
gether with the characteristics of clinical material. Figure 1
shows the quality of immunohistochemical reactions.
Quantitative Real-Time RT-PCR
Samples were stored at −80 °C until RNA preparation. In
the frozen specimens, after isolating RNA (ribonucleic
acid) and rewriting it into cDNA (complementary
deoxyribonucleic acid) in the reverse transcription reaction,
the expression level of the PTEN gene was assessed by
means of the real-time PCR (polymerase chain reaction)
method. RNeasy Mini Kit by Qiagen, a QuantiTect Re-
verse Transcription kit by Qiagen, TaqMan Array 96-
WellPlates Applied Biosystems with an appropriate set of
primers for the examined gene were used.
Fig. 1 ER expression in tumor tissue. IHC staining, original
192 D. Samulak et al.
18S rRNA (ribosomal ribonucleic acid) constituted the
internal control of the reaction. The reaction was repeated
three times for each specimen. On the basis of the Ct value
(threshold cycle—the number of reaction cycles after which
fluorescence exceeds the defined threshold) of the examined
gene and of the internal control gene the relative expression
level of RNA was calculated according to the ΔΔCt (delta,
delta Ct) approximation method.
Statistical Analysis
The occurrence of statistically significant differences between
expression of PTEN gene depending on receptors expression
and on neoplasm maturity grade was checked by means of
Kruskal—Wallis test.
The tests were carried out after obtaining a consent from
the Bioethical Commission of the Academy of Medical Sci-
ences of. Karol Marcinkowski in Poznań (Resolution number
240/04 from 05.02.2004).
The tests were carried out in the Patomorphological Labo-
ratory of the Gynaecological and Obstetric Clinical Hospital
of the University of Medical Sciences in Poznań and in the
Faculty and Institute of Histology and Embryology of the
Academy of Medical Sciences in Wrocław.
The statistical analysis was carried out in the Faculty and
Institute of IT (informatics) and Statistics of the University of
Medical Sciences in Poznań. For the sake of the analysis
STATISTICA v. 8 was used, for multiple comparisons
Kruskal—Wallis test was applied, U Mann–Whitney test
was used to carry out the descriptive statistics for individual
groups.
Results
In the final results of the histopathological examination neo-
plasm advancement grade G1 was diagnosed in 82.11 % of
patients with endometrial cancer (n =101), G2 in 9.76 % of
patients (n =12) and G3 in 8.13 % of patients (n =10).
In 29 patients with endometrial cancer, it was impossible to
mark receptors in the examined material. Out of the remaining
94, in 7 patients the lack of ER was detected and in 2 patients
the lack of PgR. Expression of PTEN gene was possible to
evaluate in 118 patients with endometrial cancer. Wherefore
the number of patients in whom receptors and gene were
marked together was 91. Taking these results into accound it
was possible to divide patients with endometrial cancer into
the following subgroups according to receptor expression
intensification level. There were 17 patients in subgroup
ER++/PgR + (strong expression of ER and strong expression
of PgR), 6 patients in subgroup ER++/PgR0 (strong expres-
sion of ER and weak or no expression of PgR), 44 patients in
ER+/PgR + (weak expression of ER and strong expression of
PgR), 17 patients in ER+/PgR0 (weak expression of ER and
weak or no expression of PgR), 5 in ER0/PgR + (no expres-
sion of ER and strong expression of PgR) and 2 patients in
subgroup ER0/PgR0 (no expression of ER and weak or no
expression of PgR). Dependecies of the presence of PTEN
expression on the receptor status of patients with endometrial
cancer are displayed in Table 1. In each receptor subgroup it
was determined whether PTEN gene expression in the exam-
ined material was higher or lower than gene expression in the
control group. Figure 2 shows summary of expression of
PTEN gene depending on expression of ER and PgR.
By means of the Kruskal—Wallis test for multiple com-
parisons the occurrence of statistically significant differences
between expression of PTEN gene in particular receptor sub-
group was checked. No statistically significant difference in
the field of the examined parameters was found.
Statistically significant differences between groups G1, G2
and G3 were examined in the event ofΔΔCt for gene PTEN .
The assumed significance level was p <0.05 (Table 2).
No statistically significant difference in gene expression
depending on neoplasm maturity grade was found.
Discussion
In this paper, apart from expression of PTEN and ER and PgR
receptors in endometrial cancer, the following issues were
examined: the occurrence of dependencies between intensifi-
cation ofPTEN expression and expression of receptors as well
as the occurrence of statistically significant differences in gene
expression depending on malignancy grade G of endometrial
cancer.
Loss of PTEN expression is connected, through trail PI3K/
AKT, with loss of control of cell proliferation and apoptosis
and with the promotion of neoplasm development [16] .
Reduction of PTEN expression ensues most frequently
through point mutations, loss of heterozygosity and promoter
hypermethylation [17]. Somatic mutations of PTEN are com-
mon in endometrial cancer but occur mainly in type I cancer
(in ca. 83 %) [10, 18–20]. Germinal mutations of PTEN occur
in Crowden syndrome in 80 % of instances [21]. Loss of
heterozygosity occur in 40 % of instances of endometrial
cancer [22–25] and hypermethylation in circa 20 %, mainly
in highly advanced cancers [26]. Matias-guiu et al. [23] report
the occurrence of mutation and reduction of PTEN expression
already during the hyperplasia stage. Similar data regarding
PTEN inactivation, during the hyperplasia stage with or with-
out atypy, occur in reports of Prat et al. [24] as well as Doll
et al. [12]. Mutter et al. [11] found decreased expression in
75% of instances of the pre-cancer stage and in 95% of type I
cancer and in 25 % of type II cancer, which let them draw the
following conclusion: disorders in PTEN expression are an
early incidents in the development process of endometrioid
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endometrial cancer. Salvesen et al. [27] found the occurrence
of promoter hypermethylation and decreased PTEN expres-
sion linked to this fact in 26 out of 138 patients (19 %) with
endometrial cancer. Tests showed statistical significance re-
garding the occurrence of hypermethylation in advanced can-
cer stages. Latta et al. [28] found mutation of gene PTEN both
in the normal endometrium exposed to oestrogens, pre-cancer
stages as well as endometrial cancer. However, the percentage
of patients with decreased expression of PTEN increased with
the advancement of changes within the endometrium and
amounted to 18–55 % for pre-cancer stages and 26–80 %
for cancer. Salvesen et al. [29] in their further research report-
ed the presence of mutations in 54 % of incidences of cancer
and statistically significant dependency between the occur-
rence of mutations and young age of patients, low advance-
ment according to FIGO, endometrioid cancer type, high
maturity grade G, the occurrence of microsatellite instability
as well as poor prognosis. Also Mackay et al. [30] noticed in
their research on 123 patients beneficial prognosis in instances
of decreased PTEN expression in women with an advanced
endometrial cancer. However, Erkanli et al. [31], finding more
significant reduction of expression in cancers than in
hyperplasia or normal endometrium, report the occurrence of
statistically significant correlation between the reduction of
expression and shorter survival time. Comparisons of expres-
sion degree of PTEN depending on neoplasm maturity were
made by Inab et al. [32] as well as Kagan et al. [33]. They
presented data which indicates a statistically significant de-
pendency between maturity grade G and gene expression.
Both testes showed more decreased expression in grade G1
and G2 than in G3. Moreover, Kagan found lower PTEN
expression in specimens with positive expression of oestrogen
and progesterone receptors. This difference was statistically
significant. Sobczuk et al. [34] examining expression of this
gene in 70 patients with cancer and 68 with normal endome-
trium found a significant difference in the reduction of PTEN
expression between these two groups. Bogusiewicz et al. [35]
examining among others PTEN expression in 45 women with
primary endometrioid endometrial cancer found the reduction
of PTEN level in 33 % of incidences and lack of correlation
between the reduction of expression of this gene and the
occurrence of endometrial cancer.
In this paper decreased expression of gene PTEN was





























ER++/PgR+ ER++/PgR0 ER+/PgR+ ER+/PgR0 ER0/PgR+ ER0/PgR0
receptor subgroups
increased expression decreased expression
Fig. 2 Relationship between
PTEN and ER and PgR
expression
Table 1 PTEN with altered expression in endometrial cancer patients (n =91)
ER++/PgR + (n =17) ER++/PgR0 (n=6) ER+/PgR + (n =44) ER+/PgR0 (n =17) ER0/PgR + (n=5) ER0/PgR0 (n =2)
PTEN Number (%) Number (%) Number (%) Number (%) Number (%) Number (%)
Increased expression 16 (94.12) 4 (66.66) 8 (18.19) 4 (23.53) 4 (80). 1 (50)
Decreased expression 1 (5.88) 2 (33.34) 36 (81.81) 13 (76.47) 1 (20) 1 (50)
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confirms the thesis about the contribution of these gene to
pathogenesis of endometrial cancer. However, a significant
difference was noticed between the percentage of patients
with overexpression and decreased expression of gene PTEN
in individual receptor subgroups. Low expression was found
in 76.47 % of patients from subgroup ER+/PgR0 and in
81.81 % of women from subgroup ER+/PgR+. In subgroups
ER++/PgR+, ER++/PgR0 and ER0/PgR + the amount of
PTEN mRNA was decreased in 5.88 %, 33.34 % and 20 %
of incidences respectively, which in comparison with world
reports is not without any meaning either. Subgroup ER0/
PgR0, in which 50 % of patients had decreased expression,
requires some explanations. However, due to the fact that this
subgroup includes only 2 people, the results might not be
reliable. Despite such a big percentage of patients with decreased
expression of gene PTEN no statistically significant dependency
regarding histological maturity grade has been found.
In research on the theory based on molecular rules of devel-
opment of endometrial cancer attention has been drawn to a
group of pharmaceuticals beingmTOR inhibitors. mTOR (mam-
malian target of the rapamycin) is a protein (serine/threonine
protein kinase) which constitutes a part of the trail regulating cell
proliferation, growth and apoptosis (mTOR-AKT-PI3K-PTEN).
In vitro tests showed sensitivity of endometrial cancer cells with
PTEN inactivation to mTOR inhibitors. It happens because loss
of PTEN leads to activation of many trails enhancing the activity
of mTOR and at the same time uncontrolled cell growth [36].
Pharmaceuticals in this group include: temsirolimus (CCI-779),
everolimus (RAD001) and deforolimus (AP23573) [10]. In
tests carried out in 19 patients in an advanced endometrial
cancer stage a partial response to treatment in 5 women
(26 %) was found as well as inhibition of the development of
the disease in 12 patients (63%) [36, 37]. Other pharmaceuticals
that are taken into account whenever PTEN expression is
decreased include PI3K inhibitors (enzastaurin) and AKT in-
hibitors (triciribine) [10]. Due to this fact it seems justified to
evaluate expression of PTEN and to begin a therapy based on
this evaluation in patients suffering from endometrial cancer,
especially in advanced incidences where other methods become
ineffective or impossible to carry out.
Tests regarding expression of PTEN gene presented in this
paper are in most cases compliant with the results obtained by
other scientists and indicate their significant usefulness in the
process of search for new endometrial cancer therapeutic
methods as well as create new possibilities regarding use of
PTEN markers as a predictive factor. However, it is a novelty
to compare gene expression in hormone-dependent and
hormone-independent groups. This gives a possibility to work
out a treatment method individualized for each patient by
means of e.g. mTOR inhibitors, PI3K inhibitors and AKT
inhibitors as well as hormonotherapy.
Conclusions
1. Decreased expression of PTEN gene and expression of
oestrogen and progesterone receptors occurs in the ma-
jority of patients with endometrial cancer.
2. Expression of PTEN gene and oestrogen and progester-
one receptors is not dependent on each other.
3. Expression of PTEN gene is not dependent on the matu-
rity grade of cancer.
4. Evaluation of expression of PTEN gene may turn out to
be a very useful tool aimed at qualifying patients for
different therapies of endometrial cancer and at searching
of new diagnostic and therapeutic methods of this cancer,
especially in relation with rare neoplasms and those with a
poor prognosis, independently on their receptor status nor
maturity grade of cancer.
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